Comparison of the Efficacy of Microneedling Alone Versus Microneedling Coupled With Either Bleomycin or 5flourouracil in the Treatment of Plantar Warts

To compare between the efficacy and safety of microneedling alone, microneedling with topical bleomycin and microneedling with 5-flurouracil in treatment of planter warts.
Microneedling will be performed on each wart using dermapen supplied with 12 needles arranged in rows. Topical anesthetic cream will be applied for 60 min before the procedures. Microneedling will be performed on each wart using dermapen. The penetration depth will be adjusted at 2-mm, endpoint is pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the warts.
Bleomycin is typically supplied in 15 U vials. The preparation will be diluted first with 7 mL normal saline ,double the amount taken from the vial by adding the same amount lidocaine (2%), so that the concentrations become 1 U/mL . The maximum total amount of bleomycin taken to each patient in one session will be 1 U/1 mL . Microneedling will be performed on the lesion using a microneedling pen type device with a 1-cm tip diameter at a 2-mm depth setting for 2-3 minutes until pinpoint bleebing occurs 1 mL of the prepared solution of bleomycin (1 U/1 mL) will be dropped on to the wart tissue using insulin syringe and occlusion will be applied for 3 hours.
5-FU is available in 10 mL vial: 500 mg/10 mL. Application of 5-FU solution will be done by dropping using an insulin syringe (1 mL)to help dropping of the solution on the warts surface. Then, the lesion will be occluded with a plaster for 3 h.
Sessions: Sessions will be performed every 2 weeks until complete cure or for maximum 6 sessions (total 3 month)

Start Date01 Jun 2026

Sponsor / Collaborator

Assiut University

NCT07201766

/ Not yet recruitingNot ApplicableIIT

The Efficacy of Intralesional Bleomycin as Compared to 5-Flourouracil (5-FU) and Triamcinolone Acetonide (TAC) for the Treatment of Keloids: A Randomized Control Trial.

The goal of this clinical trial is to learn if drug bleomycin intralesionally is beneficial than intralesional 5FU and Triamcinolone Acetonide in treating Keloids. The main questions it aims to answer are:
Does drug Bleomycin injected intrasleisonally lower the time duration to effectively treat the keloids in participants as compared to intralesional Triamcinolone Acetonide and 5-Flourouracil? Researchers will compare drug Bleomycin and 5FU plus Triamcinolone Acetonide and determine if bleomycin is better.
Participants will:
Treatment will be given in two groups by a researcher blinded of the treatment being given in each group. POSAS patient and observer scar scale will be used to assess the keloids at 0, 2, 4, 6, 8, 10, and 12 weeks and during follow ups afterwards, assessments will be carried out by another researcher who will assess the improvement on the scale of 0-no improvement, to excellent-75-100% improvement in terms of POSAS variables. Effectiveness will be indicated by 50% reduction in POSAS score from the baseline.

Start Date02 Oct 2025

Sponsor / Collaborator

King Edward Medical University

NCT07197541

/ Not yet recruitingPhase 4IIT

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts

All patients were treated as self-control. Half of the warts received bleomycin injection and the other half received pingyangmycin injection for 24 weeks. During the treatment period, before each injection, photos of the skin lesions must be taken, the diameter of the skin lesions must be measured, the DLQI(Dermatology Life Quality Index) and NRS scores(NRS scores) must be filled in, and adverse events must be recorded. Before the first treatment, HPV(Human Papilloma virus) virus typing is performed on the warts.

Start Date01 Oct 2025

Sponsor / Collaborator

Second Affiliated Hospital Zhejiang University College of

100 Clinical Results associated with Bleomycin Hydrochloride

100 Translational Medicine associated with Bleomycin Hydrochloride

100 Patents (Medical) associated with Bleomycin Hydrochloride

15,230

Literatures (Medical) associated with Bleomycin Hydrochloride

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Electrochemotherapy, as a novel therapeutic approach in the management of lentigo maligna, lentigo maligna melanoma, and acral lentiginous melanoma

Article

Author: Németh, István Balázs ; Varga, Erika ; Csányi, Ildikó ; Vass, Gábor ; Oláh, Judit ; Korom, Irma ; Baltás, Eszter ; Kis, Erika ; Rózsa, Petra ; Ócsai, Henriette ; Gyulai, Rolland

PURPOSE:

Lentigo maligna (LM), lentigo maligna melanoma (LMM), and acral lentiginous melanoma (ALM) are characterized by irregular borders and manifest on highly visible and/or surgically challenging areas. The challenge in treating these melanomas lies in preserving function and achieving satisfactory esthetic outcomes while ensuring complete surgical excision with an appropriate safety margin. We report three cases of elderly patients with LM, LMM, and ALM treated with electrochemotherapy (ECT).

MATERIALS AND METHODS:

All patients were treated according to the European Standard Operating Procedures of Electrochemotherapy protocol. Bleomycin was administered intravenously, followed by electroporation to allow better drug uptake into the tumor cells. The safety margin was ensured by electrode repositioning, and follow-up was scheduled regularly.

RESULTS:

Our patients experienced favorable outcomes: two achieved a complete response, with one requiring adjuvant topical imiquimod for suspected residual disease, while the third patient achieved a partial response. No serious adverse events were observed, and cosmetic results were superior compared to extensive surgery.

CONCLUSION:

ECT appears to be a safe and effective treatment alternative for LM, LMM, and ALM, especially in elderly patients where surgery may lead to significant morbidity. ECT can be used alone or in combination with other therapies, providing a wide safety margin and cosmetically favorable results.

31 Dec 2025·Future Science OA

Hesperidin alleviates pulmonary fibrosis by regulating EI24-mediated autophagy

Article

Author: Ma, Wen ; Zhang, Yan ; Wan, Fang

BACKGROUND:

Etoposide-induced protein 2.4 (EI24), an essential component of autophagy, is lowly expressed in pulmonary fibrosis. Hesperidin (Hes), a flavonoid, can regulate autophagy in various diseases. However, whether Hes can inhibit pulmonary fibrosis by mechanically regulating EI24-mediated autophagy has not been uncovered.

METHODS:

RLE-6TN cells were treated with transforming growth factor β1 (TGF-β1) and rats were injected with bleomycin (BLM) to construct the pulmonary fibrosis model. The effect of Hes on pulmonary fibrosis was evaluated by cell counting kit-8, immunofluorescence, hematoxylin and eosin, masson trichome staining and western blotting.

RESULTS:

Hes reduced cell viability of TGF-β1-induced RLE-6TN cells. Administration of Hes restored the decrease in autophagy marker levels in TGF-β1-induced RLE-6TN cells. Hes inhibited the transcriptional and translational levels of α-SMA, collagen I and fibronectin that were increased by TGF-β1 in RLE-6TN cells. Mechanically, Hes restored EI24 expression, and EI24 knockdown reversed the effect of Hes on the expressions of autophagy and fibrosis-related proteins. Additionally, Hes enhanced autophagy and fibrosis markers, which were worsened by EI24 knockdown in BLM-induced rats.

CONCLUSION:

Hes activated autophagy by upregulating EI24, which improved pulmonary fibrosis both in vitro and in vivo.

01 Dec 2025·Current Stem Cell Research & Therapy

Human Wharton’s Jelly Mesenchymal Stem Cells and their Extracellular Vesicles in the Management of Bleomycin-induced Lung Injury in Model Animals: A Comparative Preclinical Study Focused on Histomorphometric Analysis

Article

Author: Arumugam, Sabareeswaran ; Sreelatha, Harikrishnan Vijayakumar ; Kasoju, Naresh ; Krishnan, Anand

Introduction::

Pulmonary fibrosis, a condition characterized by excessive lung tissue scarring, remains a significant therapeutic challenge. Given the potential of human Wharton’s jelly- derived mesenchymal stem cells (hWJ-MSCs) and their extracellular vesicles (hWJ-MSC-EVs) as minimally invasive and scalable therapeutic options for pulmonary fibrosis in clinical settings, this study investigates the potential of hWJ-MSCs and hWJ-MSC-EVs in mitigating bleomycin-induced lung injury in C57BL/6J mice.

Methods::

hWJ-MSCs were cultured and characterized for their ability to differentiate into osteogenic, adipogenic, and chondrogenic lineages. EVs were successfully induced via serum starvation, purified using ultracentrifugation, and characterized for their protein and nucleic acid content, size distribution, and EV markers. A bleomycin-induced pulmonary fibrosis model was established in C57BL/6J mice. Mice were monitored for weight loss, mortality, and lung fibrosis severity following treatment with hWJ-MSCs and hWJ-MSC-EVs. Histological analysis and Ashcroft scoring were used to assess lung fibrosis.

Results::

Bleomycin administration in mice resulted in significant weight loss, increased mortality, and severe lung fibrosis, as demonstrated by histological analysis and Ashcroft scoring. Treatment with hWJ-MSCs and hWJ-MSC-EVs significantly alleviated these symptoms. Mice receiving these treatments exhibited improved body weight, enhanced survival rates, and reduced lung fibrosis, with notable improvements in alveolar structure and decreased fibrotic tissue deposition.

Conclusions::

These findings highlight the potential of hWJ-MSCs and hWJ-MSC-EVs as therapeutic agents in treating pulmonary fibrosis by reducing inflammation and promoting lung tissue repair, offering a potential new avenue for regenerative therapy in severe lung diseases. Future research directions involve elucidating the molecular pathways involved in tissue repair, optimizing therapeutic delivery, and conducting comprehensive clinical evaluations.

News (Medical) associated with Bleomycin Hydrochloride

04 Jun 2025

·pipelinereview.com

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

– Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma – ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy Compared to eBEACOPP, a Standard of Care Regimen in Europe – Second Approval in Frontline Hodgkin Lymphoma Broadens ADCETRIS’ Therapeutic Reach, Adding to Six Previously Approved, Distinct Indications for ADCETRIS in the European Union OSAKA, Japan & CAMBRIDGE, MA, USA I June 03, 2025 I Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS ® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2025. The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary safety and efficacy endpoints, with BrECADD demonstrating significantly superior safety as assessed by treatment-related morbidity (TRMB) and non-inferior progression-free survival (PFS) in comparison to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP), a standard of care treatment in Europe 1 . “Today’s approval represents a significant advancement for patients with Hodgkin lymphoma in the European Union,” said Teresa Bitetti, president of the Global Oncology Business Unit at Takeda. “This approval reinforces the role of ADCETRIS as a backbone in the treatment of specific lymphomas, offering healthcare professionals greater flexibility to tailor treatment plans according to individual patient needs. We’re proud to contribute another impactful option for those diagnosed with this challenging disease.” ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in the European Union (EU) in six distinct indications. This decision marks the second approval for an ADCETRIS-based combination regimen for frontline Hodgkin lymphoma, broadening the spectrum of available treatments for patients who historically have had limited options. “With BrECADD, patients now have a treatment option that not only offers greater curative potential 2* but also significantly reduces treatment-related morbidity compared to eBEACOPP,” said Peter Borchmann, MD, PhD, University Hospital of Cologne, Germany, and trial chairman of the HD21 study. “This new ADCETRIS-based combination therapy may offer a new standard of care for frontline treatment of adults with advanced stage Hodgkin lymphoma, contributing to improved long-term outcomes for patients.” About the HD21 Trial The HD21 study is a Phase 3, multi-country, prospective, open-label, randomized, multicenter trial conducted by the German Hodgkin Study Group (GHSG) with a PET-response adapted designed to assess the feasibility, efficacy, safety and tolerability of BrECADD, a novel, rationally designed, CD30-intensified frontline regimen for patients with advanced Hodgkin lymphoma. Enrolled patients with newly diagnosed, Stage IIb with large mediastinal mass and/or extranodal lesions, Stage III or IV Hodgkin lymphoma were randomized to receive two cycles of either escalated BEACOPP or BrECADD, respectively, followed by interim PET staging. A decision is then made if patients received a further two or four cycles of escalated BEACOPP or BrECADD. The HD21 trial aims to evaluate a new treatment regimen to minimize side effects, while maintaining similar responses to treatment. The study has co-primary endpoints: safety is assessed by treatment-related morbidity (TRMB) (superiority), a novel endpoint focused on clinically relevant, acute toxicities of primary chemotherapy, and efficacy is assessed by PFS (non-inferiority). Secondary endpoints are tumor response (complete response [CR] rate), overall survival (OS), infertility rate at one year, second malignancies, frequency of adverse events, therapy adherence and quality of life. About ADCETRIS® (brentuximab vedotin) ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Pfizer’s proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells. ADCETRIS injection for intravenous infusion has received FDA approval for eight indications: Health Canada granted ADCETRIS approval with conditions for relapsed or refractory Hodgkin lymphoma and sALCL in 2013, and non-conditional approval for post-autologous stem cell transplantation (ASCT) consolidation treatment of Hodgkin lymphoma patients at increased risk of relapse or progression in 2017, adults with pcALCL or CD30-expressing MF who have had prior systemic therapy in 2018, for previously untreated Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine in 2019, and for previously untreated adult patients with sALCL, peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumors express CD30, in combination with cyclophosphamide, doxorubicin, prednisone in 2019. ADCETRIS received conditional marketing authorization from the European Commission in October 2012, and the specific obligations of the conditional marketing authorization were fulfilled in May 2022. The approved indications in the European Union are: (1) for the treatment of adult patients with previously untreated CD30-positive Stage III or IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine (AVD), (2) for the treatment of adult patients with CD30-positive Hodgkin lymphoma at increased risk of relapse or progression following ASCT, (3) for the treatment of adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, (4) for the treatment of adult patients with relapsed or refractory sALCL, (5) for the treatment of adult patients with previously untreated sALCL in combination with CHP, (6) for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy and (7) for the treatment of adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD). ADCETRIS has received marketing authorization by regulatory authorities in 80 countries for relapsed or refractory Hodgkin lymphoma and sALCL. See Important Safety Information below. ADCETRIS is being evaluated broadly in more than 70 clinical trials, including a Phase 3 study in first-line Hodgkin lymphoma (ECHELON-1) and another Phase 3 study in first-line CD30-positive peripheral T-cell lymphomas (ECHELON-2), as well as trials in many additional types of CD30-positive malignancies. Pfizer and Takeda fund joint development costs for ADCETRIS on a 50:50 basis, except in Japan where Takeda is solely responsible for development costs. Please see the full Prescribing Information, including BOXED WARNING, for ADCETRIS here . About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com . Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Footnotes: *While late relapse is rare, PFS status after 5 years does not guarantee cure. Patients should be monitored and encouraged to report any return of symptoms as appropriate. References: SOURCE: Takeda Pharmaceutical

Phase 3Drug ApprovalClinical ResultImmunotherapyADC

04 Jun 2025

·pmlive.com

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

Takeda has received approval from the European Commission (EC) for its Pfizer-partnered blood cancer drug Adcetris (brentuximab vedotin). The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) to treat newly diagnosed stage 2b Hodgkin lymphoma (HL) in adults with risk factors/3/4. The authorisation follows a recent recommendation from the European Medicines Agency’s human medicines committee and was based on positive results from the phase 3 HD21 study. The trial achieved its co-primary endpoints, with the Adcetris regimen demonstrating significantly improved safety, as assessed by treatment-related morbidity, and non-inferior progression-free survival compared to escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone (eBEACOPP), a standard of care in Europe. HD21 trial chairman, Peter Borchmann, University Hospital of Cologne, said: “With [the Adcetris regimen], patients now have a treatment option that not only offers greater curative potential but also significantly reduces treatment-related morbidity compared to eBEACOPP. “This new Adcetris-based combination therapy may offer a new standard of care for front-line treatment of adults with advanced stage HL, contributing to improved long-term outcomes for patients.” HL originates from abnormal lymphocytes and is distinguished from other types of lymphoma by the presence of Reed-Sternberg cells, which typically carry the CD30 protein on their surface. Approximately 82,469 new cases of the disease were reported globally in 2022. Adcetris, an antibody-drug conjugate (ADC) directed at CD30, is already approved in the EU for six other adult indications and the EC’s latest decision marks the second approval for an Adcetris-based combination regimen for front-line HL. Teresa Bitetti, president of Takeda’s global oncology business unit, said the approval “represents a significant advancement for patients with HL in the EU”. “This approval reinforces the role of Adcetris as a backbone in the treatment of specific lymphomas, offering healthcare professionals greater flexibility to tailor treatment plans according to individual patient needs. We’re proud to contribute another impactful option for those diagnosed with this challenging disease,” Bitetti added. Takeda is responsible for Adcetris’ commercialisation everywhere except the US and Canada, where Pfizer holds commercialisation rights.

Drug ApprovalClinical ResultPhase 3ADCImmunotherapy

29 Apr 2025

·pmlive.com

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

Takeda has received a new recommendation from the European Medicines Agency’s human medicines committee for its Pfizer-partnered blood cancer drug Adcetris (brentuximab vedotin). The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD30-directed antibody-drug conjugate (ADC) be approved alongside etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) to treat newly diagnosed stage IIb Hodgkin lymphoma (HL) in adults with risk factors/III/IV. The CHMP’s positive opinion was supported by results from the late-stage HD21 trial evaluating Adcetris plus ECADD against escalated doses of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone, a standard of care in Europe. The study met its co-primary endpoints, with the Adcetris regimen demonstrating significantly improved safety as assessed by treatment-related morbidity and non-inferior progression-free survival. HL is a relatively aggressive cancer that originates in the lymphatic system. It is distinguished from other types of lymphoma by the presence of Reed-Sternberg cells, which typically carry the CD30 protein on their surface. Adcetris, which is already approved in Europe for six indications, belongs to a class of cancer drugs that combine the selectivity of antibodies with the cell-killing properties of chemotherapy or other anti-cancer agents. Unlike chemotherapy, which works by attacking lots of different cells as well as the cancer, ADCs are designed to target and kill tumour cells while sparing healthy ones. The European Commission will now review the CHMP’s recommendation as it makes a decision on Adcetris in this indication. Takeda is responsible for Adcetris’ commercialisation everywhere except the US and Canada, where Pfizer holds commercialisation rights. The latest announcement for Adcetris comes less than a month after the National Institute for Health and Care Excellence (NICE) recommended in final draft guidance that Adcetris be used on the NHS alongside doxorubicin, vinblastine and dacarbazine to treat patients with untreated stage 3 or 4 CD30-positive HL. The decision made Adcetris the first drug to be recommended specifically for previously untreated late-stage classical HL and followed an “improved confidential discount” on the treatment’s list price offered by Takeda, NICE said.

Drug ApprovalADCClinical ResultAccelerated ApprovalNDA

100 Deals associated with Bleomycin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D03229	Bleomycin Hydrochloride	L01DC01	DB00290

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Germinoma	Japan	Nippon Kayaku Co., Ltd.	31 May 2004
Neoplasms	China	Bristol Myers Squibb Co.	18 Oct 2000
Embryonal Carcinoma	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Esophageal Carcinoma	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Esophageal Carcinoma	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968
Ganglioglioma	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Gliosarcoma	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968
Head and Neck Neoplasms	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968
Lung Cancer	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Lymphoma	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968
Lymphoma	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Skin Neoplasms	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Skin Neoplasms	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968
Thyroid Cancer	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968
Thyroid Cancer	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Uterine Cervical Cancer	Japan	Bristol Myers Squibb Co.	16 Dec 1968
Uterine Cervical Cancer	Japan	Nippon Kayaku Co., Ltd.	16 Dec 1968

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO2025	Not Applicable	Nonseminomatous Germ Cell Tumor	103	etoposide-cisplatin (EP) with 40-60% dose reduction (Stabilizing CT)	cuyoxwlaeu(huqvaeobhm) = umxfxebxru roizuumukc (dbomnhzgol ) View more	Positive	17 Oct 2025
				bleomycin, etoposide, and cisplatin (BEP) (Full-dose CT)	cuyoxwlaeu(huqvaeobhm) = refhhwxkbf roizuumukc (dbomnhzgol ) View more
PB3154 (EHA2025)	Not Applicable	Hodgkin's Lymphoma	148	ABVD	aivvhiiiul(iwrukbkvaj) = mqlbpmiudd iumtnxqhym (yhgqqvqqac ) View more	Positive	14 May 2025
				AVD	aivvhiiiul(iwrukbkvaj) = lnfpyapsuc iumtnxqhym (yhgqqvqqac ) View more
ASCO_GU2025	Not Applicable	Nonseminomatous Germ Cell Tumor	179	BEP (bleomycin, etoposide, cisplatin)	naqifrekiv(nocvsoaofz) = pslitbneua lphkidqanq (qnlwicgpwr, 20.6 - 126.7) View more	Negative	13 Feb 2025
096 (SGO2022)	Not Applicable	Ovarian Germ Cell Cancer	213	BEP chemotherapy	kdztrbphwb(mxzwsnmvdl) = there were no significant differences in DFS and OS between BEP and TC groups kaohqixkup (pkkqvhayhl ) View more	Positive	01 Aug 2022
				TC chemotherapy
NCT02247869 (Pubmed \| Ann Hematol) Manual	Phase 2	Hodgkin's Lymphoma	96	G-CSF+Doxorubicin Hydrochloride+Bleomycin Hydrochloride+Vinblastine Sulfate+Dacarbazine	lbbbovqcgh(wxdgneoehh) = dvpytsxaii sertmhqiem (lnkdnkwhqr ) View more	Positive	01 Oct 2021
APAO2021	Not Applicable	-	-	Bleomycin sclerotherapy (1IU/ml)	ydzzoencmg(syjfpuwlxv) = umjlxagkrj uiratngqvg (wucullnrys )	-	05 Sep 2021
NCT01726374 (The 111, Pubmed \| Eur Urol)	Phase 3	Testicular Germ Cell Tumor Adjuvant	246	One cycle of BE500P	pqzztkfugy(cqqnfrvovr) = mjsoxivftw sbalhvfieq (mdkpwcsysj, 0.3 - 3.7) View more	-	01 Mar 2020
ASTRO2019	Not Applicable	Hodgkin's Lymphoma	-	Complete Bleomycin (CB)	hmrdisnzbi(evtzliaplr) = acxdozfdpf ietnsktopb (wtksqtbofc ) View more	-	01 Sep 2019
				Incomplete Bleomycin (IB)	hmrdisnzbi(evtzliaplr) = zmtqtobmti ietnsktopb (wtksqtbofc ) View more
NCT01435018 (CTgov)	Phase 3	HIV Infections	334	Tenofovir+Etoposide+Emtricitabine+Efavirenz (ET+ART)	xrprtwvpda = amiwiweydr tnmjfwofux (rkdxkrxzoj, lkwmmlthja - ialdiwuayk) View more	-	08 Apr 2019
				Tenofovir+Emtricitabine+Efavirenz+Paclitaxel (PTX) (PTX+ART)	xrprtwvpda = jkcwjttppr tnmjfwofux (rkdxkrxzoj, plxxctqjhr - qsokwramep) View more
NCT00026208 (CTgov)	Phase 2	Hodgkin's Lymphoma	76	Low-dose radiotherapy (RT)+Etoposide+Cyclophosphamide+prednisone+Doxorubicin+Bleomycin+Vincristine (Stanford V-C + Low-dose Radiotherapy)	krnbwgpgxr = ddmffjeayn doatvzcpfg (umpsklheyy, dzlormaowt - zfwqalxzbp) View more	-	15 May 2018
				Etoposide+Cyclophosphamide+prednisone+Doxorubicin+Bleomycin+Vincristine (Stanford V-C Only)	krnbwgpgxr = yisovyowqk doatvzcpfg (umpsklheyy, uwksuyxdxh - umallwlfiv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bleomycin Hydrochloride

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation